CardiASK
CardiASK: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Instructions for use: method and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. In case of impaired renal function
- 11. For violations of liver function
- 12. Drug interactions
- 13. Analogs
- 14. Terms and conditions of storage
- 15. Terms of dispensing from pharmacies
- 16. Reviews
- 17. Price in pharmacies
Latin name: CardiASK
ATX code: B01AC06
Active ingredient: acetylsalicylic acid (acetylsalicylic acid)
Producer: CJSC "Kanonfarma production", Russia
Description and photo update: 2019-13-08
Prices in pharmacies: from 33 rubles.
Buy
CardiASK is a non-steroidal anti-inflammatory drug (NSAID), an antiplatelet agent.
Release form and composition
Dosage form KardiASK - enteric-coated tablets: round, convex on both sides, white, with a smooth shiny surface, slight roughness is possible (10 pcs. In blister packs, in a cardboard box 1, 2 or 3 packs).
Active ingredient: acetylsalicylic acid, in 1 tablet - 50 or 100 mg.
Additional components: plasdon K-90, plasdon S-630, microcrystalline cellulose, calcium stearate, lactose, tween-80, collikut MAE 100P, talc, titanium dioxide, propylene glycol, corn starch, castor oil.
Pharmacological properties
CardiASK is characterized by antiaggregatory action. It also has antipyretic, analgesic and anti-inflammatory properties.
Pharmacodynamics
The mechanism of the antiplatelet action of acetylsalicylic acid (ASA) is the irreversible inhibition of cyclooxygenase (COX-1). This leads to suppression of platelet aggregation and suppression of the synthesis of thromboxane A 2. The antiplatelet effect is most pronounced in the effect on platelets, which lose the ability to re-synthesize cyclooxygenase. The duration of the antiplatelet effect is approximately 7 days after a single dose, and it is more pronounced in male patients than in women.
ASA increases the fibrinolytic activity of blood plasma and reduces the content of vitamin K-dependent coagulation factors (X, IX, VII, II).
Pharmacokinetics
After oral administration, ASA is rapidly and almost completely absorbed from the gastrointestinal tract, while being partially metabolized during absorption. During and after absorption, the active component of CardiASA passes into the main metabolite - salicylic acid, which is metabolized in the liver under the influence of enzymes. As a result, metabolites such as salicyluric acid, glucuronide salicylate and phenyl salicylate are formed, which are found in urine and many tissues.
In female patients, metabolic processes proceed more slowly due to the weaker activity of enzymes in the blood serum. The maximum content of ASA in blood plasma is recorded 10-20 minutes after oral administration, salicylic acid - in 0.3-2 hours. Since the tablets are acid-resistant, the release of ASA does not occur in the stomach (the tablet coating effectively prevents the drug from dissolving), but in the duodenum with its alkaline environment. For this reason, absorption of ASA in the form of enteric-coated tablets is slowed down within 3-6 hours compared to conventional uncoated tablets.
Salicylic acid and ASA bind intensively to blood plasma proteins (by 66–98% depending on the dose) and are rapidly distributed in the body systems. Salicylic acid crosses the placental barrier and is excreted in breast milk.
The excretion of salicylic acid is dose-dependent, since its metabolism is limited by the capabilities of the enzymatic system. The half-life reaches 2-3 hours when taking ASA in small doses and 15 hours when taking the drug in high doses (usually when used as an analgesic). Unlike other salicylates, repeated administration of the drug does not lead to the accumulation of non-hydrolyzed ASA in the blood serum. Salicylic acid and its metabolites are excreted in the urine. In patients with normal renal function, 80-100% of the dose of CardiASA taken once is excreted through the kidneys within 24-72 hours.
Indications for use
According to the instructions, CardiASK is used to prevent the following diseases:
- Transient disorders of cerebral circulation;
- Stroke, including in patients with transient disorders of cerebral circulation;
- Thromboembolism after operations and invasive interventions on the vessels, including angioplasty and endarterectomy of the carotid arteries, coronary artery bypass grafting and arteriovenous bypass grafting;
- Deep vein thrombosis, thromboembolism of the pulmonary artery and its branches, including with prolonged immobilization of the patient due to extensive surgical intervention;
- Acute myocardial infarction in patients with risk factors such as diabetes mellitus, arterial hypertension, hyperlipidemia, obesity, old age, smoking;
- Recurrent myocardial infarction.
Also, CardiASK is used to treat unstable angina.
Contraindications
- Hepatic / renal impairment;
- Gastrointestinal bleeding;
- Erosive and ulcerative lesions of the gastrointestinal tract;
- Hemorrhagic diathesis;
- Aspirin triad (combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses with intolerance to acetylsalicylic acid or other NSAIDs);
- Bronchial asthma caused by the intake of salicylates and NSAIDs;
- The simultaneous use of methotrexate at a dose of 15 mg per week or more;
- Age under 18;
- I and III trimester of pregnancy;
- Lactation;
- Hypersensitivity to acetylsalicylic acid or other NSAIDs.
Relative (diseases and conditions requiring caution when using CardiASK due to the risk of complications):
- Gout;
- Hyperuricemia;
- A history of ulcerative lesions of the gastrointestinal tract or intestinal bleeding;
- Bronchial asthma;
- Chronic respiratory diseases;
- Polyposis of the nasal mucosa;
- Hay fever;
- Allergic reactions to drugs;
- Vitamin K deficiency;
- Deficiency of glucose-6-phosphate dehydrogenase;
- Concomitant use of methotrexate at a dose of less than 15 mg per week;
- II trimester of pregnancy.
Instructions for the use of CardiASK: method and dosage
CardiASK should be taken orally before meals with plenty of liquid.
Recommended doses:
- Prophylaxis for suspected acute myocardial infarction: 100-200 mg per day or 300 mg every other day (it is recommended to chew the first tablet so that it is quickly absorbed);
- Prevention of acute myocardial infarction in the presence of risk facts: 100 mg per day or 300 mg every other day;
- Unstable angina pectoris, as well as prevention of repeated myocardial infarction, stroke, transient cerebrovascular accident, thromboembolic complications after invasive studies or surgical interventions on the vessels: 100-300 mg per day;
- Prevention of deep vein thrombosis, thromboembolism of the pulmonary artery and its branches: 100-200 mg per day or 300 mg every other day.
The duration of therapy is determined individually, but CardiASK is used for a long time.
Side effects
- Respiratory system: bronchospasm;
- Hematopoietic system: increased bleeding; rarely - anemia;
- Digestive system: pain in the abdomen, increased activity of hepatic transaminases, heartburn, nausea, vomiting, ulcers of the gastric mucosa and 12 duodenal ulcers (including with perforation), gastrointestinal bleeding;
- Central nervous system: tinnitus, dizziness;
- Allergic reactions: urticaria, anaphylactic reactions, Quincke's edema.
Overdose
Salicylate intoxication (occurs when taking ASA in daily doses exceeding 100 mg / kg for more than 2 days) can be the result of prolonged use of CardiASA in toxic doses in the case of an incorrectly prescribed therapeutic regimen (chronic intoxication) or a single accidental or intentional intake a toxic dose of a drug for a child or an adult (acute intoxication).
Signs of chronic intoxication with salicylic acid derivatives are not specific and are often difficult to diagnose. Mild intoxication usually occurs only after repeated administration of ASA in significant doses and is expressed in hearing loss, tinnitus, headache, dizziness, excessive sweating, nausea and vomiting, and impaired consciousness. After reducing the dose of CardiASK, this symptomatology disappears. Tinnitus can manifest itself at a plasma ASA level of 150–300 μg / ml. More severe symptoms are recorded when the ASA level in blood plasma exceeds 300 μg / ml.
A characteristic sign of acute intoxication is a severe violation of the acid-base balance, the symptoms of which differ depending on the severity of the intoxication and the age of the patient. In children, metabolic acidosis is a typical sign.
Treatment of intoxication is carried out in accordance with approved standards, and its direction is determined by the clinical picture and the severity of intoxication. Therapy is mainly aimed at removing CardiASA from the body and restoring the acid-base state and water-electrolyte balance. Overdose is considered especially dangerous in elderly patients.
Overdose symptoms of mild to moderate severity include respiratory alkalosis, tachypnea, hyperventilation, excessive sweating, profuse sweating, headache, dizziness, hearing loss, tinnitus, blurred consciousness, nausea, vomiting.
As a treatment, gastric lavage, repeated intake of activated carbon, restoration of the acid-base state and water-electrolyte balance, forced alkaline diuresis are recommended.
Symptoms of a moderate to severe overdose are:
- neurological disorders [inhibition of the central nervous system (confusion, convulsions, drowsiness, coma) and toxic encephalopathy];
- tinnitus, deafness;
- respiratory disorders (asphyxia, hyperventilation, depression of the respiratory center, noncardiogenic pulmonary edema);
- hyperpyrexia;
- respiratory alkalosis, accompanied by compensatory metabolic acidosis;
- hematological disorders (hypoprothrombinemia, prolongation of prothrombin time, a number of conditions from inhibition of platelet aggregation to coagulopathy);
- dysfunction of the cardiovascular system (suppression of cardiac activity, lowering blood pressure, arrhythmias);
- gastrointestinal bleeding;
- violation of water and electrolyte balance (dehydration);
- impaired glucose metabolism [ketoacidosis, hypoglycemia (often in children), hyperglycemia];
- renal dysfunction from oliguria to the onset of renal failure, accompanied by hyponatremia, hypernatremia, hypokalemia.
In this case, the patient is immediately admitted to a specialized hospital for emergency therapy, which consists of gastric lavage, repeated intake of activated carbon, restoration of the acid-base state and water-electrolyte balance, hemodialysis, forced alkaline diuresis and the appointment of symptomatic therapy.
special instructions
CardiASK can cause bronchospasm, bronchial asthma attack and other hypersensitivity reactions. Patients with the following diseases are at risk: a history of bronchial asthma, chronic respiratory diseases, polyposis of the nasal mucosa, hay fever, allergic reactions to other drugs (manifested, inter alia, by skin rashes, itching, urticaria).
Taken in high doses, CardiASA can cause gout in predisposed patients (i.e., in patients with decreased uric acid excretion).
Patients receiving acetylsalicylic acid are at risk of gastrointestinal bleeding, and bleeding of varying degrees during and after surgery.
Patients with diabetes mellitus undergoing hypoglycemic therapy should bear in mind that ASA in high doses can have a hypoglycemic effect.
During treatment, it is recommended to refrain from drinking alcohol, since ethanol increases the risk of damage to the mucous membrane of the gastrointestinal tract and lengthening the bleeding time.
Influence on the ability to drive vehicles and complex mechanisms
Reception of CardiASK does not affect the ability to drive vehicles and perform work associated with increased concentration of attention and rapid psychomotor reactions.
Application during pregnancy and lactation
Reception of CardiASK in high doses in the first trimester of pregnancy increases the risk of fetal defects (heart defects, cleft palate), therefore, its appointment during this period is contraindicated. In the second trimester of pregnancy, salicylates are prescribed only after a careful correlation of the benefits to the mother and the potential risk to the fetus, mainly in daily doses of no more than 150 mg and for a short period of time.
In the third trimester of pregnancy, CardiASK in high doses (more than 300 mg per day) can provoke increased bleeding in the mother and the fetus, early closure of the ductus arteriosus in the fetus, inhibition of labor, and taking the drug immediately before childbirth often leads to intracranial hemorrhages, especially in premature babies children. Therefore, the use of the drug during this period is prohibited.
ASA and its metabolites in small concentrations pass into breast milk. Accidental intake of the drug during breastfeeding does not cause adverse reactions in the child and does not require the cancellation of feedings. However, with long-term therapy or taking CardiASK in high doses, lactation should be stopped immediately.
With impaired renal function
CardiASK is contraindicated in severe renal failure (CC less than 30 ml / min). In case of renal dysfunction with CC more than 30 ml / min, the drug is used with caution.
For violations of liver function
CardiASC is not prescribed for class B and higher liver failure in accordance with the Child-Pugh scale. With liver dysfunctions below class B in accordance with this scale, it must be taken with caution.
Drug interactions
- Methotrexate: its renal clearance decreases, due to which the effects of methotrexate are enhanced; the incidence of side effects from the hematopoietic organs increases;
- Digoxin: the concentration in the blood plasma increases, the effects are enhanced;
- Heparin, indirect anticoagulants, thrombolytic and antiplatelet drugs (including ticlopidine), hypoglycemic agents (insulin and sulfonylurea derivatives), valproic acid: their effect is enhanced;
- Uricosuric drugs (including benzbromarone): their effect is weakened;
- Ethanol: additive effect noted;
- Glucocorticosteroids (GCS): excretion increases and the effect of acetylsalicylic acid weakens, and after the abolition of GCS, the risk of ASA overdose increases;
- Anticoagulants, thrombolytics, antiplatelet drugs: the risk of bleeding increases;
- Ibuprofen: the effectiveness of ASA decreases.
Analogs
Analogues of CardiASK are: Anopirin, Trombogard 100, ASK-cardio, Walsh-asalgin, Aspikor, Trombo ASS, Aspinat, Aspinat 300, Aspinat Cardio, Taspir, Aspirin, Aspirin 1000, Aspirin Cardio, Aspirin York, Aspirin Express, Plidol 300, Acecardol, Mikristin, Acenterin, Acetylsalicylic acid, Colfarit, Acylpirin, Zorex Morning, Atsbirin, Bufferin, Trombopol, Upsarin UPSA, Eich-el-Payne.
Terms and conditions of storage
Store at temperatures up to 25 ° C in a place out of the reach of children, protected from light and moisture.
Shelf life is 2 years.
Terms of dispensing from pharmacies
Available without a prescription.
Reviews about CardiASK
According to reviews, CardiASK is effective and has a pronounced therapeutic effect. However, it is not possible to compare the effectiveness of the drug and its analogues. Also, patients like its low cost.
Experts also speak well of the drug. Very often, CardiASK is prescribed for the prevention of thrombosis of various etiologies, stroke and myocardial infarction.
Price for CardiASK in pharmacies
The approximate price for CardiASK with a dosage of 50 mg is 51–63 rubles (for a pack of 30 tablets) or 92–105 rubles (for a pack of 60 tablets). You can buy a drug with a dosage of 100 mg for about 64–82 rubles (for a pack of 30 tablets) or 111–131 rubles (for a pack of 60 tablets).
CardiASK: prices in online pharmacies
|
Drug name Price Pharmacy |
|
CardiASK 50 mg enteric coated tablets 30 pcs. RUB 33 Buy |
|
CardiASK 100 mg enteric coated tablets 30 pcs. 35 RUB Buy |
|
CardiASK 100 mg enteric-coated tablets 60 pcs. RUB 39 Buy |
|
KardiASK 50 mg enteric-coated tablets 60 pcs. RUB 50 Buy |
|
Cardiac pills p.o. enteric solution. 50mg 30 Pcs. RUB 59 Buy |
|
Cardiac pills p.o. enteric solution. 50mg 60 Pcs. RUB 86 Buy |
|
Cardiac pills p.o. enteric solution. 100mg 60 pcs. RUB 90 Buy |
Maria Kulkes Medical journalist About the author
Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
